血清PSA、PSAD、ALP联合检测对前列腺癌骨转移的临床诊断价值

Clinical diagnostic value analysis of serum PSA, PSAD and ALP for bone metastasis of prostate cancer

目的探讨血清前列腺特异性抗原(PSA)、前列腺特异性抗原密度(PSAD)、碱性磷酸酶(ALP)联合检测对前列腺癌(PCa)骨转移的诊断价值。方法回顾性分析98例PCa患者的临床资料,根据是否发生骨转移分为骨转移组(n=56)和非骨转移组(n=42)。检测患者的血清PSA、PSAD、ALP水平,分析3项指标单独及联合检测对PCa骨转移的诊断价值。结果 98例PCa患者中,56例患者发生骨转移,骨转移率为57.1%。骨转移组患者的PSA和PSAD值均高于非骨转移组,差异均有统计学意义(P﹤0.05)。ALP+PSA+PSAD联合诊断PCa骨转移的灵敏度(98.34%)、阳性预测值(90.53%)、阴性预测值(92.33%)及约登指数(73.84)均高于PSA、PSAD、ALP单独诊断的结果。结论血清PSA、PSAD、ALP联合检测对于PCa骨转移具有较高的诊断价值,值得临床推广应用。

Objective To investigate the clinical diagnostic value of serum prostate-specific antigen（PSA）, prostatespecific antigen density（PSAD）, and alkaline phosphatase（ALP） for bone metastasis of prostate cancer（PCa）. Method Clinical data of 98 PCa patients were retrospectively analyzed. Patients were divided into bone metastasis group（n=56）and non-bone metastasis group（n=42）. The levels of serum PSA, PSAD and ALP were collected and analyzed for bone metastasis of PCa. Result The bone metastasis rate of the study was 57.1%（56/98）. The PSA and PSAD were significantly higher in bone metastasis group than those of non-bone metastasis group（P〈0.05）. The sensitivity（98.34%）, positive predictive value（90.53%）, negative predictive value（92.33%） and Youden index（73.84） of the combined diagnosis of ALP＋PSA＋PSAD were significantly higher than those of PSA or PSAD or ALP alone. Conclusion The combined application of PSA, PSAD and ALP can improve the diagnostic efficacy of bone metastasis in PCa, and is worthy of clinical applications.